Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Hadassah Medical Center: Lerer Bernard

Last updated June 2021 - Hadassah Medical Center

List of Publications

(1) Moskovich D, Alfandari A, Finkelshtein Y, Weisz A, Katzav A, Kidron D, et al. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. Cancer Lett 2021;501:224-233.

(2) Kamitaki N, Sekar A, Handsaker RE, de Rivera H, Tooley K, Morris DL, et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 2020;582(7813):577-581.

(3) Krol FJ, Hagin M, Vieta E, Harazi R, Lotan A, Strous RD, et al. Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials? Eur Neuropsychopharmacol 2020;32:1-11.

(4) Alkelai A, Greenbaum L, Heinzen EL, Baugh EH, Teitelbaum A, Zhu X, et al. New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Prog Neuro-Psychopharmacol Biol Psychiatry 2019;94.

(5) Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, et al. Publisher Correction: Gene expression imputation across multiple brain regions provides insights into schizophrenia risk (Nature Genetics, (2019), 51, 4, (659-674), 10.1038/s41588-019-0364-4). Nat Genet 2019;51(6):1068.

(6) Ben-Ari H, Lifschytz T, Wolf G, Rigbi A, Blumenfeld-Katzir T, Merzel TK, et al. White matter lesions, cerebral inflammation and cognitive function in a mouse model of cerebral hypoperfusion. Brain Res 2019;1711:193-201.

(7) Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, et al. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nat Genet 2019;51(4):659-674.

(8) Wolf G, Lifschytz T, Ben-Ari H, Tatarskyy P, Merzel TK, Lotan A, et al. Effect of chronic unpredictable stress on mice with developmental under-expression of the Ahi1 gene: Behavioral manifestations and neurobiological correlates. Transl Psychiatry 2018;8(1).

(9) Ni G, Gratten J, Wray NR, Lee SH, Ripke S, Neale BM, et al. Age at first birth in women is genetically associated with increased risk of schizophrenia. Sci Rep 2018;8(1).

(10) Zai CC, Lee FH, Tiwari AK, Lu JY, De Luca V, Maes MS, et al. Investigation of the HSPG2Gene in tardive dyskinesia-new data and meta-analysis. Front Pharmacol 2018;9(SEP).

(11) Lotan A, Lifschytz T, Wolf G, Keller S, Ben-Ari H, Tatarsky P, et al. Differential effects of chronic stress in young-adult and old female mice: Cognitive-behavioral manifestations and neurobiological correlates. Mol Psychiatry 2018;23(6):1432-1445.

(12) Lerer B. From freud to biology, from genes to medicines: A 40 year perspective. Isr J Psychiatry 2018;55(3):65-71.

(13) Sarner-Levin K, Canetti L, Latzer Y, Bonne O, Lerer B, Bachar E. Anorexia nervosa, selflessness, and gender-role identity: A study of daughters and parents. Isr J Psychiatry 2018;55(1):25-34.

(14) Eitan R, Fontaine D, Benoît M, Giordana C, Darmon N, Israel Z, et al. One year double blind study of high vs low frequency subcallosal cingulate stimulation for depression. J Psychiatr Res 2018;96:124-134.

(15) Wolf G, Lotan A, Lifschytz T, Ben-Ari H, Merzel TK, Tatarskyy P, et al. Differentially severe cognitive effects of compromised cerebral blood flow in aged mice: Association with myelin degradation and microglia activation. Front Aging Neurosci 2017;9(JUN).

(16) Lotan A, Lifschytz T, Mernick B, Lory O, Levi E, Ben-Shimol E, et al. Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: Translational evidence from the stress-resilient Ahi1 knockout mouse. Mol Psychiatry 2017;22(6):884-899.

(17) McLaughlin RL, Schijven D, Van Rheenen W, Van Eijk KR, O'Brien M, Kahn RS, et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat Commun 2017;8.

(18) Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 2017;49(1):27-35.

(19) Li M, Huang L, Grigoroiu-Serbanescu M, Bergen SE, Landén M, Hultman CM, et al. Convergent Lines of Evidence Support LRP8 as a Susceptibility Gene for Psychosis. Mol Neurobiol 2016;53(10):6608-6619.

(20) Hagelkruys D, Böhm C, Motschnig R, Kertzman S, Sirota A, Lerer B, et al. Adapting a stand-alone computerized cognitive test battery for online use - A case-study in the context of users with special needs. Comput Hum Behav 2016;63:757-768.

(21) Franke B, van Hulzen KJE, Arias-Vasquez A, Bralten J, Hoogman M, Klein M, et al. Genetic influences on schizophrenia and subcortical brain volumes: Large-scale proof of concept. Nat Neurosci 2016;19(3):420-431.

(22) Li X, Zhang W, Lencz T, Darvasi A, Alkelai A, Lerer B, et al. Common variants of IRF3 conferring risk of schizophrenia. J Psychiatr Res 2015;64:67-73.

(23) Bulik-Sullivan B, Loh P-, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet 2015;47(3):291-295.

(24) Greenbaum L, Lerer B. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes. Front Neurol 2015;6(FEB).

(25) Lotan A, Lifschytz T, Lory O, Goelman G, Lerer B. Amygdalar disconnectivity could underlie stress resilience in the Ahi1 knockout mouse: Conclusions from a resting-state functional MRI study. Mol Psychiatry 2014;19(2):144.

(26) Lotan A, Lifschytz T, Slonimsky A, Broner EC, Greenbaum L, Abedat S, et al. Neural mechanisms underlying stress resilience in Ahi1 knockout mice: Relevance to neuropsychiatric disorders. Mol Psychiatry 2014;19(2):243-252.

(27) Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R. Neurotransmitters and electroconvulsive therapy. J ECT 2014;30(2):116-121.

(28) Luo X-, Li M, Huang L, Steinberg S, Mattheisen M, Liang G, et al. Convergent lines of evidence support CAMKK2 as a schizophrenia susceptibility gene. Mol Psychiatry 2014;19(7):774-783.

(29) Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511(7510):421-427.

(30) Greenbaum L, Goldwurm S, Zozulinsky P, Lifschytz T, Cohen OS, Yahalom G, et al. Do tardive dyskinesia and l-dopa induced dyskinesia share common genetic risk factors? An exploratory study. J Mol Neurosci 2013;51(2):380-388.

(31) Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013;45(10):1150-1159.

(32) Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Procházka V, et al. Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 2013;44:1-7.

(33) Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, et al. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Front Neurosci 2013(7 APR).

(34) Greenbaum L, Rigbi A, Lipshtat N, Cilia R, Tesei S, Asselta R, et al. Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: Gene and smoking status interaction. Parkinsonism Relat Disord 2013;19(1):72-76.

(35) Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2012;12(6):513-520.

(36) Lifschytz T, Broner EC, Zozulinsky P, Slonimsky A, Eitan R, Greenbaum L, et al. Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: Serotonergic involvement. Int J Neuropsychopharmacol 2012;15(9):1307-1318.

(37) Pelov I, Teltsh O, Greenbaum L, Rigbi A, Kanyas-Sarner K, Lerer B, et al. Involvement of PTPN5, the gene encoding the striatal-enriched protein tyrosine phosphatase, in schizophrenia and cognition. Psychiatr Genet 2012;22(4):168-176.

(38) Levinson DF, Shi J, Wang K, Oh S, Riley B, Pulver AE, et al. Genome-wide association study of multiplex schizophrenia pedigrees. Am J Psychiatry 2012;169(9):963-973.

(39) Greenbaum L, Lifschytz T, Zozulinsky P, Broner EC, Slonimsky A, Kohn Y, et al. Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model. Eur Neuropsychopharmacol 2012;22(5):379-386.

(40) Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifschytz T, et al. Erratum: Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients (Psychopharmacology DOI:10.1007/s00213- 011-2499-6). Psychopharmacology 2012;220(3):643.

(41) Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifshytz T, et al. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. Psychopharmacology 2012;220(3):519-528.

(42) Alkelai A, Greenbaum L, Lupoli S, Kohn Y, Sarner-Kanyas K, Ben-Asher E, et al. Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS ONE 2012;7(1).

(43) Lerer B, Belmaker RH. Conference scene in global personalized medicine: CINP Thematic Meeting on Pharmacogenomics and Personalised Medicine in Psychiatry, Jerusalem, Israel (April 21-23, 2013). Curr Pharmacogenomics Per Med 2012;10(4):264.

(44) Stein DJ, Lerer B, Stahl S. Preface. Essent Evidence-Based Psychopharmacology, Second Edition 2012:viii.

(45) Stein DJ, Lerer B, Stahl S. Essential evidence-based psychopharmacology, second edition. Essential Evidence-Based Psychopharmacology, Second Edition; 2012. p. 1-325.

(46) Teltsh O, Kanyas-Sarner K, Rigbi A, Greenbaum L, Lerer B, Kohn Y. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol 2012;15(3):309-319.

(47) Alkelai A, Lupoli S, Greenbaum L, Kohn Y, Kanyas-Sarner K, Ben-Asher E, et al. DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. Int J Neuropsychopharmacol 2012;15(4):459-469.

(48) Alkelai A, Lupoli S, Greenbaum L, Giegling I, Kohn Y, Sarner-Kanyas K, et al. Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample. FASEB J 2011;25(11):4011-4023.

(49) Vardi N, Freedman N, Lester H, Gomori JM, Chisin R, Lerer B, et al. Hyperintensities on T2-weighted images in the basal ganglia of patients with major depression: Cerebral perfusion and clinical implications. Psychiatry Res Neuroimaging 2011;192(2):125-130.

(50) Lifschytz T, Zozulinsky P, Eitan R, Landshut G, Ohayon S, Lerer B. Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT 1A receptors: Mediation by thyroid hormone α receptors. J Pharmacol Exp Ther 2011;337(2):494-502.

(51) Greenbaum L, Levin R, Lerer E, Alkelai A, Kohn Y, Heresco-Levy U, et al. Association of Reelin (RELN) single nucleotide polymorphism rs7341475 with prepulse inhibition in the Jewish Israeli population. Biol Psychiatry 2011;69(5):e17-e18.

(52) Rigbi A, Yakir A, Sarner-Kanyas K, Pollak Y, Lerer B. Why do young women smoke VI. A controlled study of nicotine effects on attention: Pharmacogenetic interactions. Pharmacogenomics J 2011;11(1):45-52.

(53) Isserles M, Rosenberg O, Dannon P, Levkovitz Y, Kotler M, Deutsch F, et al. Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. J Affective Disord 2011;128(3):235-242.

(54) Cooper-Kazaz R, Rigbi A, Lerer B. Targeting remission by 8 weeks: When should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor? Compr Psychiatry 2011;52(1):9-16.

(55) Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011;43(10):969-978.

(56) Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 2010;25(16):2809-2817.

(57) Greenbaum L, Kanyas KS, Rigbi A, Alkelai A, Kohn Y, Lerer B. Why do young women smoke? VII COMT as a risk modifying gene for Nicotine dependence - Role of gene-gene interaction, personality, and environmental factors. Hum Psychopharmacol 2010;25(7-8):536-542.

(58) Torri F, Akelai A, Lupoli S, Sironi M, Amann-Zalcenstein D, Fumagalli M, et al. Fine mapping of AHI1 as a schizophrenia susceptibility gene: From association to evolutionary evidence. FASEB J 2010;24(8):3066-3082.

(59) Slonimsky A, Levy I, Kohn Y, Rigbi A, Ben-Asher E, Lancet D, et al. Lymphoblast and brain expression of AHI1 and the novel primate-specific gene, C6orf217, in schizophrenia and bipolar disorder. Schizophr Res 2010;120(1-3):159-166.

(60) Eitan R, Landshut G, Lifschytz T, Einstein O, Ben-Hur T, Lerer B. The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: Possible role in antidepressant-augmenting properties. Int J Neuropsychopharmacol 2010;13(5):553-561.

(61) Lifschytz T, Goltser-Dubner T, Landshut G, Lerer B. Effect of triiodothyronine on 5-HT1A and 5-HT1B receptor expression in rat forebrain and on latency to feed in the novelty suppressed feeding test. Prog Neuro-Psychopharmacol Biol Psychiatry 2010;34(4):632-638.

(62) Cooper-Kazaz R, Cohen A, Lerer B. Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine. J Clin Psychopharmacol 2010;30(2):211-212.

(63) Greenbaum L, Pelov I, Teltsh O, Lerer B, Kohn Y. No association between regulator of G-protein signaling 9 (RGS9) and schizophrenia in a Jewish population. Psychiatr Genet 2010;20(1):47-48.

(64) Ingason A, Giegling I, Cichon S, Hansen T, Rasmussen HB, Nielsen J, et al. A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. Hum Mol Genet 2010;19(7):1379-1386.

(65) Alkelai A, Kohn Y, Olender T, Sarner-Kanyas K, Rigbi A, Hamdan A, et al. Evidence for an interaction of schizophrenia susceptibility loci on chromosome 6q23.3 and 10q24.33-q26.13 in Arab Israeli families. Am J Med Genet Part B Neuropsychiatr Genet 2009;150(7):914-925.

(66) Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology 2009;206(3):491-499.

(67) Ng MYM, Levinson DF, Faraone SV, Suarez BK, Delisi LE, Arinami T, et al. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry 2009;14(8):774-785.

(68) Greenbaum L, Lerer B. Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: Recent progress and emerging open questions. Mol Psychiatry 2009;14(10):912-945.

(69) Cooper-Kazaz R, van der Deure WM, Medici M, Visser TJ, Alkelai A, Glaser B, et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affective Disord 2009;116(1-2):113-116.

(70) Rigbi A, Yakir A, Kanyas K, Pollak Y, Lerer B. Further support for a role of the His452Tyr variant in 5-HT2A receptor gene in memory functions in humans. Int J Neuropsychopharmacol 2009;12(5):723-725.

(71) Greenbaum L, Smith RC, Rigbi A, Strous R, Teltsh O, Kanyas K, et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: Protective role of a functional polymorphism in the 3′-untranslated region. Pharmacogenomics J 2009;9(2):103-110.

(72) Teltsh O, Kanyas K, Karni O, Levi A, Korner M, Hamdan A, et al. P.3.18 Mutation screening in a candidate region for schizophrenia on chromosome 20p13. Eur Neuropsychopharmacol 2009;19:S77.

(73) Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis 2009;24(1):27-53.

(74) Eitan R, Landshut G, Lerer B. Neurochemical effects of electrically induced seizures: Relevance to the antidepressant mechanism of electroconvulsive therapy. Electroconvulsive and Neuromodulation Therapies; 2009. p. 45-74.

(75) Papakostas GI, Cooper-Kazaz R, Appelhof BC, Posternak MA, Johnson DP, Klibanski A, et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: A quantitative synthesis of double-blind studies. Int Clin Psychopharmacol 2009;24(1):19-25.

(76) Holmans PA, Riley B, Pulver AE, Owen MJ, Wildenauer DB, Gejman PV, et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry 2009;14(8):786-795.

(77) Thomas P, Srivastava V, Singh A, Mathur P, Nimgaonkar VL, Lerer B, et al. Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry Res 2008;161(3):275-283.

(78) Lerer B. IJNP: A decade in perspective. Int J Neuropsychopharmacol 2008;11(8):1035-1036.

(79) Gesundheit B, Lerer B, Budowski E, Neuman T, Gomori JM, Or R. Sudden psychotic symptoms in a 28-year-old male with thymoma. J Clin Oncol 2008;26(26):4353-4355.

(80) Kohn Y, Freedman N, Lester H, Krausz Y, Chisin R, Lerer B, et al. Cerebral perfusion after a 2-year remission in major depression. Int J Neuropsychopharmacol 2008;11(6):837-843.

(81) Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008;11(5):685-699.

(82) Ludewick HP, Schwab SG, Albus M, Lerer B, Maier W, Trixler M, et al. No support for an association with TAAR6 and schizophrenia in a linked population of European ancestry. Psychiatr Genet 2008;18(4):208-210.

(83) Canetti L, Kanyas K, Lerer B, Latzer Y, Bachar E. Anorexia nervosa and parental bonding: The contribution of parent-grandparent relationships to eating disorder psychopathology. J Clin Psychol 2008;64(6):703-716.

(84) Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008;8(3):228-236.

(85) Bachar E, Kanyas K, Latzer Y, Canetti L, Bonne O, Lerer B. Depressive tendencies and lower levels of self-sacrifice in mothers, and selflessness in their anorexic daughters. Eur Eating Disord Rev 2008;16(3):184-190.

(86) Teltsh O, Kanyas K, Karni O, Levi A, Korner M, Ben-Asher E, et al. Genome-wide linkage scan, fine mapping, and haplotype analysis in a large, inbred, arab israeli pedigree suggest a schizophrenia susceptibility locus on chromosome 20p13. Am J Med Genet Part B Neuropsychiatr Genet 2008;147(2):209-215.

(87) Rigbi A, Kanyas K, Yakir A, Greenbaum L, Pollak Y, Ben-Asher E, et al. Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes Brain Behav 2008;7(2):164-172.

(88) Schwab SG, Plummer C, Albus M, Borrmann-Hassenbach M, Lerer B, Trixler M, et al. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: An association study. Psychiatr Genet 2008;18(1):25-30.

(89) Lerer B, Isserles M. From Meduna to ultrabrief: New directions for the oldest brain stimulation therapy. Brain Stimul 2008;1(2):84-85.

(90) Srivastava V, Deshpande SN, Nimgaonkar VL, Lerer B, Thelma BK. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: Role of metabolic pathway genes. Pharmacogenomics 2008;9(8):1055-1068.

(91) Pae C-, Yu H-, Amann D, Kim J-, Lee C-, Lee S-, et al. Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. J Psychiatr Res 2008;42(1):35-40.

(92) Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL, Thelma BK. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C > T polymorphism. Pharmacogenomics J 2007;7(5):305-311.

(93) Massat I, Lerer B, Souery D, Blackwood D, Muir W, Kaneva R, et al. HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study [3]. Mol Psychiatry 2007;12(9):797-798.

(94) Kohn Y, Freedman N, Lester H, Krausz Y, Chisin R, Lerer B, et al. 99mTc-HMPAO SPECT study of cerebral perfusion after treatment with medication and electroconvulsive therapy in major depression. J Nucl Med 2007;48(8):1273-1278.

(95) Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007;17(7):519-528.

(96) Segman RH, Kanyas K, Karni O, Lerer E, Goltser-Dubner T, Pavlov V, et al. Why do young women smoke? IV. Role of genetic variation in the dopamine transporter and lifetime traumatic experience. Am J Med Genet Part B Neuropsychiatr Genet 2007;144(4):533-540.

(97) Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, et al. Combined treatment with sertraline and liothyronine in major depression: A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007;64(6):679-688.

(98) Strous RD, Greenbaum L, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol 2007;10(3):321-333.

(99) Thelma BK, Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: Role of oxidative stress pathway genes. Schizophr Res 2007;92(1-3):278-279.

(100) Morar B, Schwab SG, Albus M, Maier W, Lerer B, Wildenauer DB. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet 2007;144(3):318-324.

(101) Yakir A, Rigbi A, Kanyas K, Pollak Y, Kahana G, Karni O, et al. Why do young women smoke? III. Attention and impulsivity as neurocognitive predisposing factors. Eur Neuropsychopharmacol 2007;17(5):339-351.

(102) Krausz Y, Freedman N, Lester H, Barkai G, Levin T, Bocher M, et al. Brain SPECT study of common ground between hypothyroidism and depression. Int J Neuropsychopharmacol 2007;10(1):99-106.

(103) Schwab SG, Knapp M, Sklar P, Eckstein GN, Sewekow C, Borrmann-Hassenbach M, et al. Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIα gene (PIP5K2A) with schizophrenia. Mol Psychiatry 2006;11(9):837-846.

(104) Lerer E, Kanyas K, Karni O, Ebstein RP, Lerer B. Why do young women smoke? II. Role of traumatic life experience, psychological characteristics and serotonergic genes. Mol Psychiatry 2006;11(8):771-781.

(105) Eitan R, Lerer B. Nonpharmacological, somatic treatments of depression: Electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin Neurosci 2006;8(2):241-258.

(106) Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: Pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci 2006;8(1):85-94.

(107) Greenbaum L, Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A, et al. Localization of SNPs in the CHRNB2 gene. Mol Psychiatry 2006;11(3):223.

(108) Greenbaum L, Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A, et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol Psychiatry 2006;11(3):312-322.

(109) Cheng R, Juo SH, Loth JE, Nee J, Iossifov I, Blumenthal R, et al. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry 2006;11(3):252-260.

(110) Lerer B. Recent strategies for potentiation and facilitation of antidepressant treatment: Introduction. Curr Drug Targets 2006;7(2):137.

(111) Lifschytz T, Shalom G, Lerer B, Newman ME. Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats. Eur Neuropsychopharmacol 2006;16(2):115-121.

(112) Lifschytz T, Segman R, Shalom G, Lerer B, Gur E, Golzer T, et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 2006;7(2):203-210.

(113) Amann D, Avidan N, Kanyas K, Kohn Y, Hamdan A, Ben-Asher E, et al. The trace amine receptor 4 gene is not associated with schizophrenia in a sample linked to chromosome 6q23 [3]. Mol Psychiatry 2006;11(2):119-121.

(114) Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16(2):111-117.

(115) Amann-Zalcenstein D, Avidan N, Kanyas K, Ebstein RP, Kohn Y, Hamdan A, et al. AHI1, a pivotal neurodevelopmental gene, and C6orf217 are associated with susceptibility to schizophrenia. Eur J Hum Genet 2006;14(10):1111-1119.

(116) Kohn Y, Lerer B. Excitement and confusion on chromosome 6q: The challenges of neuropsychiatric genetics in microcosm. Mol Psychiatry 2005;10(12):1062-1073.

(117) Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, Lerer B, et al. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of european sib-pair families. Biol Psychiatry 2005;58(6):446-450.

(118) Deshpande SN, Varma PG, Semwal P, Rao AR, Bhatia T, Nimgaonkar VL, et al. II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr Genet 2005;15(3):157-158.

(119) Lerer B, Segman RH, Tan E-, Basile VS, Cavallaro R, Aschauer HN, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005;8(3):411-425.

(120) Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005;75(1):21-26.

(121) Levi A, Kohn Y, Kanyas K, Amann D, Pae C-, Hamdan A, et al. Fine mapping of a schizophrenia susceptibility locus at chromosome 6q23: Increased evidence for linkage and reduced linkage interval. Eur J Hum Genet 2005;13(6):763-771.

(122) Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, et al. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005;5(1):60-69.

(123) Lifschytz T, Gur E, Lerer B, Newman ME. Erratum: Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: Regional differences (Journal of Neuroscience Methods (2004) 140 (133-139) PII: S0165-0270(04)00290-0 and DOI: 10.1016/j.jneumeth.2004.03.028). J Neurosci Methods 2005;141(2):335.

(124) Ozdemir V, Lerer B. Pharmacogenomics and the promise of personalized medicine. Pharmacogenomics, Second Edition; 2005. p. 13-50.

(125) Weiser M, Kanyas K, Malaspina D, Harvey PD, Glick I, Goetz D, et al. Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-L. Compr Psychiatry 2005;46(1):38-42.

(126) McQueen MB, Devlin B, Faraone SV, Nimgaonkar VL, Sklar P, Smoller JW, et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet 2005;77(4):582-595.

(127) Lifschytz T, Gur E, Lerer B, Newman ME. Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: Regional differences. J Neurosci Methods 2004;140(1-2 SPEC. ISS.):133-139.

(128) Park N, Juo SH, Cheng R, Liu J, Loth JE, Lilliston B, et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schipzoprenia. Mol Psychiatry 2004;9(12):1091-1099.

(129) Gur E, Lifschytz T, Van De Kar LD, Lerer B, Newman ME. Effects of triiodothyronine on 5-HT1A and 5-HT1B autoreceptor activity, and postsynaptic 5-HT1A receptor activity, in rat hypothalamus: Lack of interaction with imipramine. Psychoneuroendocrinology 2004;29(9):1172-1183.

(130) Gur E, Lerer B, Van De Kar LD, Newman ME. Chronic rTMS induces subsensitivity of post-synaptic 5-HT1A receptors in rat hypothalamus. Int J Neuropsychopharmacol 2004;7(3):335-340.

(131) Bah J, Quach H, Ebstein RP, Segman RH, Melke J, Jamain S, et al. Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. Neuroreport 2004;15(12):1987-1991.

(132) Mowry BJ, Holmans PA, Pulver AE, Gejman PV, Riley B, Williams NM, et al. Multicenter linkage study of schizophrenia loci on chromosome 22q. Mol Psychiatry 2004;9(8):784-795.

(133) Kohn Y, Danilovich E, Filon D, Oppenheim A, Karni O, Kanyas K, et al. Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: Findings from identity by descent haplotype sharing analysis. Am J Med Genet Neuropsychiatr Genet 2004;128 B(1):65-70.

(134) Mendlewicz J, Massat I, Souery D, Del-Favero J, Oruč L, Nöthen MM, et al. Serotonin transporter 5HTTLPR polymorphism and affective disorders: No evidence of association in a large European multicentre study. Eur J Hum Genet 2004;12(5):377-382.

(135) Blairy S, Linotte S, Souery D, Papadimitriou GN, Dikeos D, Lerer B, et al. Social adjustment and self-esteem of bipolar patients: A multicentric study. J Affective Disord 2004;79(1-3):97-103.

(136) Siegfried Z, Kanyas K, Latzer Y, Karni O, Bloch M, Lerer B, et al. Association Study of Cannabinoid Receptor Gene (CNR1) Alleles and Anorexia Nervosa: Differences between Restricting and Bingeing/Purging Subtypes. Am J Med Genet Neuropsychiatr Genet 2004;125 B(1):126-130.

(137) Kanyas K, Karni O, Hamdan A, Turetsky N, Kaadan M, Lerer B. Illness Recognition and Disruptiveness in Psychotic Illness. Compr Psychiatry 2004;45(2):109-113.

(138) Schwab SG, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, et al. Association of tumor necrosis factor alpha gene -G308A polymorphism with schizophrenia. Schizophr Res 2003;65(1):19-25.

(139) Bonne O, Gilboa A, Louzoun Y, Kempf-Sherf O, Katz M, Fishman Y, et al. Cerebral blood flow in chronic symptomatic mild traumatic brain injury. Psychiatry Res Neuroimaging 2003;124(3):141-152.

(140) Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M, et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003;3(5):277-283.

(141) Lerer B, Segman RH, Hamdan A, Kanyas K, Karni O, Kohn Y, et al. Genome scan of Arab Israeli families maps a schizophrenia susceptibility gene to chromosome 6q23 and supports a locus at chromosome 10q24. Mol Psychiatry 2003;8(5):488-498.

(142) Liu J, Juo SH, Dewan A, Grunn A, Tong X, Brito M, et al. Evidence for a putative bipolar disorder locus on 2p13-16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. Mol Psychiatry 2003;8(3):333-342.

(143) Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: Clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol 2003;6(1):41-49.

(144) Lichtigfeld FJ, Gillman MA, Lerer B, Macciardi F. Another marker for different types of depression [3] (multiple letters). Int J Neuropsychopharmacol 2003;6(1):91-93.

(145) Bonne O, Louzoun Y, Aharon I, Krausz Y, Karger H, Lerer B, et al. Cerebral blood flow in depressed patients: A methodological comparison of statistical parametric mapping and region of interest analyses. Psychiatry Res Neuroimaging 2003;122(1):49-57.

(146) Lerer B, Macciardi F. Reply to Lichtigfeld and Gillman. Int J Neuropsychopharmacol 2003;6(1):93.

(147) Dremencov E, Gur E, Lerer B, Newman ME. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry 2003;27(5):729-739.

(148) Rigbi A, Shalev-Mevorach L, Taller A, Taller Y, Lerer B. Relationship of clinical and demographic characteristics of schizophrenia patients to rehabilitation status. Isr J Psychiatry Relat Sci 2003;40(4):258-267.

(149) Agid R, Levin T, Gomori JM, Lerer B, Bonne O. T2-weighted image hyperintensities in major depression: Focus on the basal ganglia. Int J Neuropsychopharmacol 2003;6(3):215-224.

(150) Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003;72(1):185-190.

(151) Gur E, Lifschytz T, Lerer B, Newman ME. Effects of triiodothyronine and imipramine on basal 5-HT levels and 5-HT1 autoreceptor activity in rat cortex. Eur J Pharmacol 2002;457(1):37-43.

(152) Gur E, Dremencov E, Garcia F, Van de Kar LD, Lerer B, Newman ME. Functional effects of chronic electroconvulsive shock on serotonergic 5-HT1A and 5-HT1B receptor activity in rat hippocampus and hypothalamus. Brain Res 2002;952(1):52-60.

(153) Dremencov E, Gur E, Lerer B, Newman ME. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hypothalamus. Prog Neuro-Psychopharmacol Biol Psychiatry 2002;26(6):1029-1034.

(154) Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: A review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002;5(3):255-275.

(155) Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, et al. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27(1):105-119.

(156) Schwab SG, Hallmayer J, Freimann J, Lerer B, Albus M, Borrmann-Hassenbach M, et al. Investigation of linkage and association/linkage disequilibrium of HLA A-, DQA1-, DQB 1-, AND DRB1-alleles in 69 sib-pair- and 89 trio-families with schizophrenia. Am J Med Genet Neuropsychiatr Genet 2002;114(3):315-320.

(157) Segman RH, Shapira Y, Modai I, Hamdan A, Zislin J, Heresco-Levy U, et al. Angiotensin converting enzyme gene insertion/deletion polymorphism: Case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia. Am J Med Genet Neuropsychiatr Genet 2002;114(3):310-314.

(158) Massat I, Souery D, Del-Favero J, Van Gestel S, Serretti A, Macciardi F, et al. Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association study of affective disorders. Am J Med Genet Neuropsychiatr Genet 2002;114(2):177-185.

(159) Gur E, Dremencov E, Van De Kar LD, Lerer B, Newman ME. Effects of chronically administered venlafaxine on 5-HT receptor activity in rat hippocampus and hypothalamus. Eur J Pharmacol 2002;436(1-2):57-65.

(160) Segman RH, Heresco-Levy U, Yakir A, Goltser T, Strous R, Greenberg DA, et al. Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 2002;51(3):261-263.

(161) Kohn Y, Lerer B. Genetics of Schizophrenia: A review of linkage findings. Isr J Psychiatry Relat Sci 2002;39(4):240-251.

(162) Segman RH, Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia [2]. Mol Psychiatry 2002;7(2):137-139.

(163) Cichon S, Schumacher J, Müller DJ, Hürter M, Windemuth C, Strauch K, et al. A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. Hum Mol Genet 2001;10(25):2933-2944.

(164) Schumacher J, Cichon S, Richter C, Aboujamra R, Albus M, Borrmann-Hassenbach M, et al. Fine-mapping of chromosomal region 8q24 in bipolar affective disorder. Am J Med Genet Neuropsychiatr Genet 2001;105(7):610.

(165) Lerer B, Shapira B. Time-dependent sensitization and ECT [1]. Mol Psychiatry 2001;6(5):500.

(166) Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S, et al. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 2001;6(5):579-585.

(167) Sklar P, Schwab SG, Williams NM, Daly M, Schaffner S, Maier W, et al. Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. Nat Genet 2001;28(2):126-128.

(168) Cichon S, Schmidt-Wolf G, Schumacher J, Müller DJ, Hürter M, Schulze TG, et al. A possible susceptibility locus for bipolar affective disorder in chromosomal region 10q25-q26. Mol Psychiatry 2001;6(3):342-349.

(169) Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001;6(2):225-229.

(170) Nimgaonkar VL, Faraone SV, Lerer B, Mallet J, Sherrington R, Maier W. Impact of overlapping recruitment on psychiatric genetic studies. Am J Med Genet Neuropsychiatr Genet 2001;105(2):139-140.

(171) Liu J, Juo SH, Terwilliger JD, Grunn A, Tong X, Brito M, et al. A follow-up linkage study supports evidence for a bipolar affective disorder locus on chromosome 21q22. Am J Med Genet Neuropsychiatr Genet 2001;105(2):189-194.

(172) Souery D, Van Gestel S, Massat I, Blairy S, Adolfsson R, Blackwood D, et al. Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: A Multicenter Association Study. Biol Psychiatry 2001;49(5):405-409.

(173) Gur E, Dremencov E, Lerer B, Newman ME. Functional effects of corticosterone on 5-HT1A and 5-HT1B receptor activity in rat brain: In vivo microdialysis studies. Eur J Pharmacol 2001;411(1-2):115-122.

(174) Agid O, Shalev AY, Lerer B. Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. J Clin Psychiatry 2001;62(3):169-173.

(175) Kohn Y, Zislin J, Agid O, Hanin B, Troudart T, Shapira B, et al. Increased prevalence of negative life events in subtypes of major depressive disorder. Compr Psychiatry 2001;42(1):57-63.

(176) Gur E, Lerer B, Dremencov E, Newman ME. Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 2000;11(13):2925-2929.

(177) Lerer B, Mendlewicz J. Vaeiability of 5-HT2C receptor CYS23SER polymorphism in European populations and vulnerability to affective disorder. Am J Med Genet Neuropsychiatr Genet 2000;96(4):484.

(178) Kanyas K, Segman RH, Agid O, Lerer B. The molecular genetics of cigarette smoking: Demographic and environmental complexities. Am J Med Genet Neuropsychiatr Genet 2000;96(4):505.

(179) Karni O, Yakir A, Kanyas K, Turetsky N, Lerer B. Age at onset in sibling pairs with schizophrenia and schizoaffective disorder. Am J Med Genet Neuropsychiatr Genet 2000;96(4):505.

(180) Eckstein GN, Schwab SG, Hallmayer J, Albus M, Lerer B, Maier W, et al. A genome-wide survey for transmission disequilibrium in schizophrenia. Am J Med Genet Neuropsychiatr Genet 2000;96(4):552-553.

(181) Schwab SG, Eckstein GN, Gabel S, Hallmayer J, Lerer B, Albus M, et al. Susceptibility locus for schizophrenia on 10p: Searching for a candidate. Am J Med Genet Neuropsychiatr Genet 2000;96(4):461.

(182) Segman RH, Levy UH, Finkel B, Greenberg D, Yakir A, Shlaffman M, et al. 5-HT2A receptor polymorphism and susceptibility to tardive dyskinesia in patients with chronic schizophrenia. Am J Med Genet Neuropsychiatr Genet 2000;96(4):526.

(183) Segman RH, Levy U, Finkel B, Greenberg D, Lerner A, Yakir A, et al. Additive contribution of DRD3gly and HT2CRser alleles to susceptibility to tardive dyskinesia in patients with chronic schizophrenia. Am J Med Genet Neuropsychiatr Genet 2000;96(4):529-530.

(184) Liu J, Juo SH, Terwilliger JD, Grunn A, Tong X, Brito M, et al. Further analysis of chromosome 21q22 augments prior evidence for linkage to bipolar affective disorder. Am J Med Genet Neuropsychiatr Genet 2000;96(4):483.

(185) Cichon S, Schumacher J, Muller DJ, Hürter M, Albus M, Borrmann-Hassenbach M, et al. Systematic search for susceptibility genes in bipolar affective disorder. Am J Med Genet Neuropsychiatr Genet 2000;96(4):467-468.

(186) Schumacher J, Cichon S, Albus M, Borrmann-Hassenbach M, Franzek E, Fritze J, et al. No evidence for an X-chromosomal locus for bipolar affective disorder in 64 German and 4 Israeli families. Am J Med Genet Neuropsychiatr Genet 2000;96(4):548.

(187) Shapira B, Newman ME, Gelfin Y, Lerer B. Blunted temperature and cortisol responses to ipsapirone in major depression: Lack of enhancement by electroconvulsive therapy. Psychoneuroendocrinology 2000;25(5):421-438.

(188) Newman ME, Agid O, Gur E, Lerer B. Pharmacological mechanisms of T3 augmentation of antidepressant action. Int J Neuropsychopharmacol 2000;3(2):187-191.

(189) Shapira B, Tubi N, Lerer B. Balancing speed of response to ECT in major depression and adverse cognitive effects: Role of treatment schedule. J ECT 2000;16(2):97-109.

(190) Agid O, Kohn Y, Lerer B. Environmental stress and psychiatric illness. Biomed Pharmacother 2000;54(3):135-141.

(191) Dremencov E, Gur E, Lerer B, Newman ME. Subchronic fluoxetine administration to rats: Effects on 5-HT autoreceptor activity as measured by in vivo microdialysis. Eur Neuropsychopharmacol 2000;10(4):229-236.

(192) Canetti L, Bachar E, Bonne O, Agid O, Lerer B, De-Nour AK, et al. The impact of parental death versus separation from parents on the mental health of Israeli adolescents. Compr Psychiatry 2000;41(5):360-368.

(193) Hranilovic D, Schwab SG, Jernej B, Knapp M, Lerer B, Albus M, et al. Serotonin transporter gene and schizophrenia: Evidence for association/linkage disequilibrium in families with affected siblings. Mol Psychiatry 2000;5(1):91-95.

(194) Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2C(ser) and DRD3(gly) alleles to susceptibility. Psychopharmacology 2000;152(4):408-413.

(195) Frisch A, Michaelovsky E, Rockah R, Amir I, Hermesh H, Laor N, et al. Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur Neuropsychopharmacol 2000;10(3):205-209.

(196) Schwab SG, Hallmayer J, Albus M, Lerer B, Eckstein GN, Borrmann M, et al. A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: Support for loci on chromosome 10p and 6. Mol Psychiatry 2000;5(6):638-649.

(197) Levinson DF, Holmans P, Straub RE, Owen MJ, Wildenauer DB, Gejman PV, et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: Schizophrenia linkage collaborative group III. Am J Hum Genet 2000;67(3):652-663.

(198) Shapira B, Lerer B. Speed of response to bilateral ECT: An examination of possible predictors in two controlled trials. J ECT 1999;15(3):202-206.

(199) Souery D, Lipp O, Rivelli SK, Massat I, Serretti A, Cavallini C, et al. Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: A multicenter association study. Am J Med Genet Neuropsychiatr Genet 1999;88(5):527-532.

(200) Newman ME, Li Q, Gelfin Y, Van de Kar LD, Lerer B. Low doses of ipsapirone increase growth hormone but not oxytocin secretion in normal male and female subjects. Psychopharmacology 1999;145(1):99-104.

(201) Lerer B. The neurobiology of ECT: The road ahead. J ECT 1999;15(1):1-4.

(202) Lerer B, Shapira B, Bloch M, Hanin B, Trudart T, Alexander JR, et al. Possible precipitants of psychiatric hospitalization in patients with major depression: Results from the Jerusalem Collaborative Depression Project. Depression Anxiety 1999;9(4):156-162.

(203) Lerer B, Gelfin Y, Shapira B. Neuroendocrine evidence for age-related decline in central serotonergic function. Neuropsychopharmacology 1999;21(2):321-322.

(204) Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME. 5-HT(1A) Receptor function in normal subjects on clinical doses of fluoxetine: Blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 1999;20(6):628-639.

(205) Gur E, Dremencov E, Lerer B, Newman ME. Venlafaxine: Acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur J Pharmacol 1999;372(1):17-24.

(206) Bonne O, Krausz Y, Aharon Y, Gelfin Y, Chisin R, Lerer B. Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers. Psychopharmacology 1999;143(1):24-28.

(207) Bachar E, Lerer B, Shapira B. Increment in reminiscing after ECT: Possible connections to neuropsychologic changes [2]. J ECT 1999;15(2):165-166.

(208) Gur E, Lerer B, Newman ME. Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo: Relationship to serotonin autoreceptor activity. J Pharmacol Exp Ther 1999;288(1):81-87.

(209) Wildenauer DB, Schwab SG, Maier W, Lerer B. Searching for genes in schizophrenia. Acta Neuropsychiatr 1999;11(2):50-53.

(210) Morag M, Morag A, Reichenberg A, Lerer B, Yirmiya R. Psychological variables as predictors of rubella antibody titers and fatigue - A prospective, double blind study. J Psychiatr Res 1999;33(5):389-395.

(211) Shapira B, Zislin J, Gelfin Y, Osher Y, Gorfine M, Souery D, et al. Social adjustment and self-esteem in remitted patients with unipolar and bipolar affective disorder: A case-control study. Compr Psychiatry 1999;40(1):24-30.

(212) Agid O, Shapira B, Zislin J, Ritsner M, Hanin B, Murad H, et al. Environment and vulnerability to major psychiatric illness: A case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol Psychiatry 1999;4(2):163-172.

(213) Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4(3):247-253.

(214) Aita VM, Liu J, Knowles JA, Terwilliger JD, Baltazar R, Grunn A, et al. A comprehensive linkage analysis of chromosome 21q22 supports prior evidence for a putative bipolar affective disorder locus. Am J Hum Genet 1999;64(1):210-217.

(215) Wittekindt O, Schwab SG, Burgert E, Knapp M, Albus M, Lerer B, et al. Association between hSKCa3 and schizophrenia not confirmed by transmission disequilibrium test in 193 offspring/parents trios. Mol Psychiatry 1999;4(3):267-270.

(216) Freymann J, Schwab SG, Knapp M, Albus M, Lerer B, Hallmayer J, et al. Association studies of HLA genes in families with linkage to chromosome 6p. Am J Med Genet Neuropsychiatr Genet 1998;81(6):517.

(217) Wildenauer DB, Knapp M, Albus M, Lerer B, Borrmann M, Segman R, et al. Association/linkage disequilibrium of G-Olfα in 59 families with schizophrenic index patients in the presence of linkage. Am J Med Genet Neuropsychiatr Genet 1998;81(6):524.

(218) Hallmayer J, Schwab SG, Albus M, Lerer B, Zill P, Hanses C, et al. A potential susceptibility locus for schizophrenia on 22q12,13: Re-evaluation in 72 families. Am J Med Genet Neuropsychiatr Genet 1998;81(6):529.

(219) Aita VM, Liu J, Terwilliger JD, Baltazar R, Grunn A, Loth JE, et al. A follow-up linkage analysis of chromosome 21 continues to provide evidence for a putative bipolar affective disorder locus. Am J Med Genet Neuropsychiatr Genet 1998;81(6):476.

(220) Schwab SG, Hallmayer J, Albus M, Lerer B, Hanses C, Kanyas K, et al. A potential susceptibility locus on chromosome 10p14-p11 in 72 families with schizophrenia. Am J Med Genet Neuropsychiatr Genet 1998;81(6):528-529.

(221) Liu J, Aita VM, Knowles JA, Terwilliger JD, Baltazar R, Grunn A, et al. A genome-wide scan for bipolar affective disorder. Am J Med Genet Neuropsychiatr Genet 1998;81(6):462.

(222) Wildenauer DB, Schwab SG, Hallmayer J, Lerer B, Albus M, Borrman M, et al. Genome scan for autosomal genes conferring risk to schizophrenia in a German/ Israeli sample. Am J Med Genet Neuropsychiatr Genet 1998;81(6):454.

(223) Lerer B. The neurobiology of ECT: The road taken. J ECT 1998;14(3):149-152.

(224) Newman ME, Gur E, Shapira B, Lerer B. Neurochemical mechanisms of action of ECS: Evidence from in vivo studies. J ECT 1998;14(3):153-171.

(225) Krausz Y, Bonne O, Gorfine M, Karger H, Lerer B, Chisin R. Age-related changes in brain perfusion of normal subjects detected by 99mTc-HMPAO SPECT. Neuroradiology 1998;40(7):428-434.

(226) Vallada HP, Collier DA, Curtis D, Sham PC, Vallada H, Kunugi H, et al. A transmission disequilibrium and linkage analysis of D22S278 marker alleles in 574 families: Further support for a susceptibility locus for schizophrenia at 22q12. Schizophr Res 1998;32(2):115-121.

(227) Schwab SG, Hallmayer J, Albus M, Lerer B, Hanses C, Kanyas K, et al. Further evidence for a susceptibility locus on chromosome 10p14-p11 in 72 families with Schizophrenia by nonparametric linkage analysis. Am J Med Genet Neuropsychiatr Genet 1998;81(4):302-307.

(228) Morag M, Yirmiya R, Lerer B, Morag A. Influence of socioeconomic status on behavioral, emotional and cognitive effects of rubella vaccination: A prospective, double blind study. Psychoneuroendocrinology 1998;23(4):337-351.

(229) Gelfin Y, Gorfine M, Lerer B. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 1998;155(2):290-292.

(230) Newman ME, Shapira B, Lerer B. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: A critical review. Int J Neuropsychopharmacol 1998;1(1):49-69.

(231) Shapira B, Tubi N, Drexler H, Lidsky D, Calev A, Lerer B. Cost and benefit in the choice of ECT schedule: Twice versus three times weekly ECT. Br J Psychiatry 1998;172(JAN.):44-48.

(232) Amar A, Segman RH, Shtrussberg S, Sherman L, Safirman C, Lerer B, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol 1998;1(1):41-44.

(233) Schwab SG, Hallmayer J, Lerer B, Albus M, Borrmann M, Hönig S, et al. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am J Hum Genet 1998;63(4):1139-1152.

(234) Knowles JA, Rao PA, Cox-Matise T, Loth JE, De Jesus GM, Levine L, et al. No evidence for significant linkage between bipolar affective disorder and chromosome 18 pericentromeric markers in a large series of multiplex extended pedigrees. Am J Hum Genet 1998;62(4):916-924.

(235) Souery D, Lipp O, Serretti A, Mahieu B, Rivelli SK, Cavallini C, et al. European Collaborative Project on Affective Disorders: Interactions between genetic and psychosocial vulnerability factors. Psychiatr Genet 1998;8(4):197-205.

(236) Schreiber S, Lerer B. "Failure to thrive" in elderly depressed patients: A new concept or a different name for an old problem? Isr J Psychiatry Relat Sci 1997;34(2):108-114.

(237) Heresco-Levy U, Greenberg D, Lerer B, Javitt DC, Brown WA. Serum Neuroleptic Levels during Reduced Dose Fluphenazine Decanoate Maintenance Therapy. Isr J Psychiatry Relat Sci 1997;34(4):281-289.

(238) Gur E, Berman E, Lerer B, Newman ME. In vivo cyclic AMP responses in rat brain are not modified by chronic electroconvulsive shock. Eur Neuropsychopharmacol 1997;7(3):189-193.

(239) Bloch M, Schwartzman Y, Bonne O, Lerer B. Concurrent treatment of nonresistant major depression with desipramine and lithium: A double-blind, placebo-controlled study. J Clin Psychopharmacol 1997;17(1):44-48.

(240) Kohn Y, Ebstein RP, Heresco-Levy U, Shapira B, Nemanov L, Gritsenko I, et al. Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 1997;7(1):39-43.

(241) Gur E, Lerer B, Newman ME. Chronic electroconvulsive shock and 5-HT autoreceptor activity in rat brain: An in vivo microdialysis study. J Neural Transm 1997;104(8-9):795-804.

(242) Bleich A, Koslowsky M, Dolev A, Lerer B. Post-traumatic stress disorder and depression: An analysis of comorbidity. Br J Psychiatry 1997;170(MAY):479-482.

(243) Segman RH, Ebstein RP, Heresco-Levy U, Gorfine M, Avnon M, Gur E, et al. Schizophrenia, chronic hospitalization and the 5-HT(2C) receptor gene. Psychiatr Genet 1997;7(2):75-78.

(244) Kotler M, Cohen H, Segman R, Gritsenko I, Nemanov L, Lerer B, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry 1997;2(3):251-254.

(245) Schwab SG, Eckstein GN, Hallmayer J, Lerer B, Albus M, Borrmann M, et al. Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis. Mol Psychiatry 1997;2(2):156-160.

(246) Ebstein RP, Macciardi F, Heresco-Levi U, Serretti A, Blaine D, Verga M, et al. Evidence for an association between the dopamine d3 receptor gene DRD3 and schizophrenia. Hum Hered 1997;47(1):6-16.

(247) Bonne O, Krausz Y, Gorfine M, Karger H, Gelfin Y, Shapira B, et al. Cerebral hypoperfusion in medication resistant, depressed patients assessed by Tc99m HMPAO SPECT. J Affect Disord 1996;41(3):163-171.

(248) Bonne O, Krausz Y, Shapira B, Bocher M, Karger H, Gorfine M, et al. Increased cerebral blood flow in depressed patients responding to electroconvulsive therapy. J Nucl Med 1996;37(7):1075-1080.

(249) Lerer B, Gillon D, Lichtenberg P, Gorfine M, Gelfin Y, Shapira B. Interrelationship of age, depression, and central serotonergic function: Evidence from fenfluramine challenge studies. Int Psychogeriatr 1996;8(1):83-102.

(250) Gur E, Lerer B, Newman ME. Acute or chronic lithium does not affect agonist-stimulated inositol trisphosphate formation in rat brain in vivo. Neuroreport 1996;7(2):393-396.

(251) Shapira B, Lidsky D, Gorfine M, Lerer B. Electroconvulsive therapy and resistant depression: Clinical implications of seizure threshold. J Clin Psychiatry 1996;57(1):32-38.

(252) Krausz Y, Bonne O, Marciano R, Yaffe S, Lerer B, Chisin R. Brain SPECT imaging of neuropsychiatric disorders. Eur J Radiol 1996;21(3):183-187.

(253) Maier W, Minges J, Eckstein N, Brodski C, Albus M, Lerer B, et al. Genetic relationship between dopamine transporter gene and schizophrenia: Linkage and association. Schizophr Res 1996;20(1-2):175-180.

(254) Wildenauer DB, Hallmayer J, Schwab SG, Albus M, Eckstein GN, Zill P, et al. Searching for susceptibility genes in schizophrenia by genetic linkage analysis. COLD SPRING HARBOR SYMP QUANT BIOL 1996;61:845-850.

(255) Wildenauer DB, Schwab SG, Albus M, Hallmayer J, Lerer B, Maier W, et al. Additional Support for Schizophrenia Linkage on Chromosomes 6 and 8: A Multicenter Study. Am J Med Genet 1996;67(6):580-594.

(256) Gelfin Y, Lerer B, Lesch KP, Gorfine M, Allolio B. Complex effects of age and gender on hypothermic, adrenocorticotrophic hormone and cortisol responses to ipsapirone challenge in normal subjects. Psychopharmacology 1995;120(3):356-364.

(257) Segman RH, Gorfine M, Lerer B, Shapira B. Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy. Psychopharmacology 1995;119(4):440-448.

(258) Kohn Y, Newman ME, Lerer B, Orr SP, Pitman RK. Absence of reduced platelet adenylate cyclase activity in Vietnam veterans with PTSD. Biol Psychiatry 1995;37(3):205-208.

(259) Shapira B, Gorfine M, Lerer B. A prospective study of lithium continuation therapy in depressed patients who have responded to electroconvulsive therapy. CONVULSIVE THER 1995;11(2):80-85.

(260) Alexander JR, Benjamin J, Lerer B, Baron M, Belmaker RH. Frequency of positive family history in bipolar patients in a catchment-area population. Prog Neuro-Psychopharmacol Biol Psychiatry 1995;19(3):367-373.

(261) Lerer B, Shapira B, Calev A, Tubi N, Drexler H, Kindler S, et al. Antidepressant and cognitive effects of twice-versus three-times-weekly ECT. Am J Psychiatry 1995;152(4):564-570.

(262) Schwab SG, Albus M, Hallmayer J, Hönig S, Borrmann M, Lichtermann D, et al. Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib–pair linkage analysis. Nat Genet 1995;11(3):325-327.

(263) Lerer B, Shapira B. How resistant is resistant depression? Focus on electroconvulsive therapy. Eur Neuropsychopharmacol 1994;4(3):211-212.

(264) Segman R, Newman ME, Lerer B. Serotonin stimulation of GTP binding in rat hippocampal membranes and the action of antidepressant drugs. Eur Neuropsychopharmacol 1994;4(3):318.

(265) Gelfin G, Lesch KP, Lerer B. Effect of normal aging on 5-HT1A receptor mediated temperature and hormone responses. Eur Neuropsychopharmacol 1994;4(3):406-407.

(266) Bloch M, Schwartzmann Y, Bonne O, Lerer B. Does concurrent lithium administration potentiate the antidepressant effect of desipramine? Eur Neuropsychopharmacol 1994;4(3):299-300.

(267) Gur E, Rogel-Fuchs Y, Newman ME, Lerer B. Effects of antidepressants on cyclic AMP responses in the living rat. Eur Neuropsychopharmacol 1994;4(3):317-318.

(268) Shapira B, Gorfine M, Lidsky D, Lerer B. Seizure threshold and the treatment of major depression by electroconvulsive therapy. Eur Neuropsychopharmacol 1994;4(3):300-301.

(269) Heresco-Levy U, Lerer B, Greenberg D, Javitt DC, Brown WA. Serum levels of fluphenazine in schizophrenic outpatients maintained on two reduced doses of fluphenazine decanoate. Eur Neuropsychopharmacol 1994;4(3):385-386.

(270) Baron M, Straub RE, Lehner T, Endicott J, Ott J, Gilliam TC, et al. Bipolar disorder and linkage to Xq28. Nat Genet 1994;7(4):461.

(271) Bonne OB, Krausz Y, Kempf O, Tubi N, Gorfine M, Bocher H, et al. Cerebral blood flow in symptomatic closed cranial injury patients. Eur Neuropsychopharmacol 1994;4(3):442.

(272) Weizmann R, Gur E, Laor N, Reiss A, Muller U, Yoresh A, et al. Platelet adenylate cyclase activity in israeli victims of iraqi Scud missile attacks with post-traumatic stress disorder. Psychopharmacology 1994;114(3):509-512.

(273) Straub RE, Lehner T, Luo Y, Loth JE, Shao W, Sharpe L, et al. A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. Nat Genet 1994;8(3):291-296.

(274) Baron M, Endicott J, Lerer B, Loth JE, Alexander JR, Simon R, et al. A pedigree series for mapping disease genes in bipolar affective disorder: Sampling, assessment, and analytic considerations. Psychiatr Genet 1994;4(1):43-55.

(275) Shapira B, Cohen J, Newman ME, Lerer B. Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biol Psychiatry 1993;33(7):531-535.

(276) Newman ME, Lerer B, Shapira B. 5-HT-1A receptor-mediated effects of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry 1993;17(1):1-19.

(277) Silver H, David D, Kaplan M, Hadjez J, Tubi N, Darnel A, et al. Factor analysis of schizophrenic symptoms and comparison of different rating scales. Schizophr Res 1993;10(1):67-75.

(278) Tubi N, Calev A, Nigal D, Shapira B, Fink M, Pass HL, et al. Subjective symptoms in depression and during the course of electroconvulsive therapy. Neuropsychiatry Neuropsychol Behav Neurol 1993;6(3):187-192.

(279) Baron M, Freimer NF, Risch N, Lerer B, Alexander JR, Straub RE, et al. Diminished support for linkage between manic depressive illness and X–chromosome markers in three Israeli pedigrees. Nat Genet 1993;3(1):49-55.

(280) Bloch M, Admon D, Bonne O, Lerer B. Electroconvulsive therapy in a depressed heart transplant patient. CONVULSIVE THER 1992;8(4):290-293.

(281) Newman ME, Lerer B, Lichtenberg P, Shapira B. Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: relation to serotonergic function. Psychopharmacology 1992;109(1-2):231-234.

(282) Shapira B, Yagmur MJ, Gropp C, Newman M, Lerer B. Effect of clomipramine and lithium on fenlfuramine-induced hormone release in major depression. Biol Psychiatry 1992;31(10):975-983.

(283) Lichtenberg P, Shapira B, Blacker M, Gropp C, Calev A, Lerer B. Effect of fenfluramine on mood: A double-blind placebo-controlled trial. Biol Psychiatry 1992;31(4):351-356.

(284) Bonne O, Krausz Y, Lerer B. SPECT imaging in psychiatry. A review. Gen Hosp Psychiatry 1992;14(5):296-306.

(285) Newman ME, Shapira B, Lerer B. Regulation of 5-hydroxytryptamine(1A) receptor function in rat hippocampus by short- and long-term administration of 5-hydroxytryptamine(1A) agonists and antidepressants. J Pharmacol Exp Ther 1992;260(1):16-20.

(286) Alexander JR, Lerer B, Baron M. Ethical issues in genetic linkage studies of psychiatric disorders. Br J Psychiatry 1992;160(JAN.):98-102.

(287) Lichtenberg P, Shapira B, Gillon D, Kindler S, Cooper TB, Newman ME, et al. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res 1992;43(2):137-146.

(288) Shapira B, Lerer B, Kindler S, Lichtenberg P, Gropp C, Cooper T, et al. Enhanced serotonergic responsivity following electroconvulsive therapy in patients with major depression. Br J Psychiatry 1992;160(FEB.):223-229.

(289) Silver H, Blacker M, Weller MPI, Lerer B. Treatment of chronic schizophrenia with cyproheptadine: A double-blind placebo-controlled study. Biol Psychiatry 1991;30(5):523-525.

(290) Newman ME, Ben-Zeev A, Lerer B. Chloroamphetamine did not prevent the effects of chronic antidepressants on 5-hydroxytryptamine inhibition of forskolin-stimulated adenylate cyclase in rat hippocampus. Eur J Pharmacol Mol Pharmacol Sect 1991;207(3):209-213.

(291) Newman ME, Shapira B, Lerer B. Effects of lithium and desimipramine on second messenger responses in rat hippocampus: relation to G protein effects. Neuropharmacology 1991;30(12):1297-1301.

(292) Bachar E, Kindler S, Schefler G, Lerer B. Reminiscing as a technique in the group psychotherapy of depression: A comparative study. Br J Clin Psychol 1991;30(4):375-377.

(293) Calev A, Edelist S, Kugelmass S, Lerer B. Performance of long-stay schizophrenics on matched verbal and visuospatial recall tasks. Psychol Med 1991;21(3):655-660.

(294) Calev A, Nigal D, Shapira B, Tubi N, Chazan S, Ben-Yehuda Y, et al. Early and long-term effects of electroconvulsive therapy and depression on memory and other cognitive functions. J Nerv Ment Dis 1991;179(9):526-533.

(295) Bachar E, Calev A, Shapira B, Lerer B. Memories in depression: Pleasant or unpleasant? Br J Psychiatry 1990;157(OCT.):623-624.

(296) Gil T, Calev A, Greenberg D, Kugelmass S, Lerer B. Cognitive functioning in Post-Traumatic Stress Disorder. J Trauma Stress 1990;3(1):29-45.

(297) Ebstein RP, Bennett ER, Hadjez J, Silver H, Yedgar S, Lerer B. Cyclic AMP second messenger signal generation in EBV-transformed lymphoblastoid cells from schizophrenic patients. J Psychiatr Res 1990;24(2):121-127.

(298) Roth D, Hamburger-Bar R, Lerer B. Peripheral versus central manifestations in the toxic interaction of lithium and pilocarpine. Biol Psychiatry 1989;25(2):153-158.

(299) Shapira B, Reiss A, Kaiser N, Kindler S, Lerer B. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affective Disord 1989;16(1):1-4.

(300) Calev A, Korin Y, Kugelmass S, Lerer B. Performance of chronic schizophrenics on matched word and design recall tasks. Biol Psychiatry 1987;22(6):699-709.

(301) Lerer B, Bleich A, Kotler M, Garb R, Hertzberg M, Levin B. Posttraumatic Stress Disorder in Israeli Combat Veterans: Effect of Phenelzine Treatment. Arch Gen Psychiatry 1987;44(11):976-981.

(302) Calev A, Korin Y, Shapira B, Kugelmass S, Lerer B. Verbal and non verbal recall by depressed and euthymic affective patients. Psychol Med 1986;16(4):789-794.

(303) Globus M, Bannet J, Lerer B, Belmaker RH. The effect of chronic bromocriptine and l-Dopa on spiperone binding and apomorphine-induced stereotypy. Psychopharmacology 1982;78(1):81-84.

(304) Lerer B, Jacobowitz J. Treatment of essential hyperhidrosis by psychotherapy. Psychosomatics 1981;22(6):536-538.

(305) Hertz DG, Lerer B. The 'rape family': family reactions to the rape victim. INT J FAM PSYCHIATRY 1981;2(3-4):301-315.

(306) Globus M, Lerer B, Hamburger R, Belmaker RH. Chronic electroconvulsive shock and chronic haloperidol administration are not additive in effects on dopamine receptors. Neuropharmacology 1981;20(11):1125-1128.

(307) Bannet J, Lerer B, Ebstein RP, Ben-David M, Belmaker RH. Lack of effect of beta-2 adrenergic stimulation on human prolactin. Psychoneuroendocrinology 1981;6(2):177-179.

(308) Lerer B, Jacobowitz J, Wahba A. Personality features in essential hyperhidrosis. Int J Psychiatry Med 1980;10(1):59-67.

(309) Lerer B, Birmacher B, Ebstein RP, Belmaker RH. 48-Hour depressive cycling induced by antidepressant. Br J Psychiatry 1980;137(2):183-185.

(310) Lerer B. Odyssey into the unknown. A resident's views on psychotherapy and supervision. ISR ANN PSYCHIATRY RELAT DISCIP 1979;17(1):74-80.

(311) Segal M, Edelstein EL, Lerer B. Interaction between delta-6-tetrahydrocannabinol (delta-6-THC) and lithium at the blood brain barrier in rats. Experientia 1978;34(5):629.

(312) Lerer B. Hyperhidrosis: A review of its psychological aspects. Psychosomatics 1977;18(5):28-31.

(313) Lerer B, Avni J, Wiesel D. Bad tidings and the hospitalized patient. Ment Health Soc 1976;3(3-4):205-211.

(314) Lerer B, Avni J. Suicide in a general hospital psychiatric department. Psychiatr Clin 1976;9(2):106-111.